KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Average (2016 - 2025)

Rigel Pharmaceuticals has reported Equity Average over the past 15 years, most recently at $254.5 million for Q4 2025.

  • Quarterly results put Equity Average at $254.5 million for Q4 2025, up 4586.16% from a year ago — trailing twelve months through Dec 2025 was $254.5 million (up 4586.16% YoY), and the annual figure for FY2025 was $197.4 million, up 1656.9%.
  • Equity Average for Q4 2025 was $254.5 million at Rigel Pharmaceuticals, up from $99.8 million in the prior quarter.
  • Over the last five years, Equity Average for RIGL hit a ceiling of $254.5 million in Q4 2025 and a floor of -$30.8 million in Q2 2024.
  • Median Equity Average over the past 5 years was -$2.1 million (2022), compared with a mean of $22.1 million.
  • Biggest five-year swings in Equity Average: crashed 1778.05% in 2023 and later surged 4586.16% in 2025.
  • Rigel Pharmaceuticals' Equity Average stood at $40.0 million in 2021, then crashed by 141.79% to -$16.7 million in 2022, then tumbled by 80.8% to -$30.2 million in 2023, then soared by 81.24% to -$5.7 million in 2024, then surged by 4586.16% to $254.5 million in 2025.
  • The last three reported values for Equity Average were $254.5 million (Q4 2025), $99.8 million (Q3 2025), and $50.3 million (Q2 2025) per Business Quant data.